Loading...
OTCM
ACBM
Market cap1mUSD
Jun 16, Last price  
0.03USD
Name

ACRO Biomedical Co Ltd

Chart & Performance

D1W1MN
OTCM:ACBM chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
4.68%
Rev. gr., 5y
5.24%
Revenues
0k
00510,0008,014,500193,536687,9641,197,500658,500000
Net income
-101k
L+139.13%
-47,490-43,428-2,248419,660-371,604-117,453-7,702,078-15,871,443-8,807,573-42,297-101,146
CFO
-196k
L+435.00%
0-48,850-34,742-463,344-140,419-59,709-199,460299,335-147,481-15,446-36,692-196,302

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Acro Biomedical Co., Ltd. focuses on the development and commercialization of dietary supplements. The company offers products such as cordycepin and powdered cordyceps, which come from a type of fungus traditionally utilized in Chinese medicinal practices. Originally founded in 2014, the organization was known as Killer Waves Hawaii, Inc. until it rebranded as Acro Biomedical Co., Ltd. in January 2017. Its operations are headquartered in Fishers, Indiana.
IPO date
Jun 23, 2016
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT